表紙
市場調査レポート - 240574

非アルコール性脂肪性肝炎:世界の治験動向

Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H2, 2015

発行 GlobalData
出版日 ページ情報 英文 195 Pages
電子版即納可
価格
Back to Top
非アルコール性脂肪性肝炎:世界の治験動向 Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H2, 2015
出版日: 2015年11月30日 ページ情報: 英文 195 Pages
概要

当レポートでは、非アルコール性脂肪性肝炎に関する臨床研究の最新動向について分析しており、地域別の治験件数、治験の段階別進行状況、被験者採用の状況、有望なスポンサー、各企業や研究機関における研究の進行状況、有望な薬剤の比較といった情報をまとめています。

イントロダクション

  • 非アルコール性脂肪性肝炎
  • 当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • アジア太平洋地域の主要5ヶ国における治験件数
    • 欧州の主要5ヶ国における治験件数
    • 北米の主要国における治験件数
    • 中東・アフリカの主要国における治験件数
    • 中南米の主要5カ国における治験件数

G7諸国での治験件数:胃腸疾患治療薬の治験における非アルコール性脂肪性肝炎の割合

G7諸国における段階別の治験件数

G7諸国での治験件数:進捗状況別

E7諸国での治験件数:胃腸疾患治療薬の治験における非アルコール性脂肪性肝炎の割合

E7諸国における段階別の治験件数

E7諸国での治験件数:進捗状況別

段階別の治験件数

  • 進行中の治験:段階別

進捗状況別の治験件数

治験の目標の達成状況

未完了の治験件数

一定期間に採用された被験者

スポンサーの種類別の治験件数

有望なスポンサー

非アルコール性脂肪性肝炎治療薬の治験に携わっている主要企業

有望な薬剤

最新の治験ニュース

治験のプロファイル

  • 主要企業の治験の概要
    • Genextra S.p.a.
    • Genfit SA
    • Cempra, Inc.
    • Raptor Pharmaceuticals Corp.
    • Nimbus Therapeutics, LLC
    • Immuron Limited
    • Gilead Sciences, Inc.
    • Galmed International Ltd.
    • Galectin Therapeutics, Inc.
    • DURECT Corporation
  • 代表的な研究機関・病院の治験の概要
    • The National Institute of Diabetes and Digestive and Kidney Diseases
    • Tehran University of Medical Sciences
    • University of California, San Diego
    • National Nutrition and Food Technology Research Institute
    • 横浜市立大学
    • Bambino Gesu Hospital and Research Institute
    • Ghent University Hospital
    • Gunma Liver Study Group
    • Hadassah Medical Organization
    • Hiroshima University Hospital

5つの代表的な治験のプロファイル

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

GlobalData's clinical trial report, "Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H2, 2015" provides an overview of Non-Alcoholic Steatohepatitis clinical trials scenario. This report provides top line data relating to the clinical trials on Non-Alcoholic Steatohepatitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 4
  • List of Figures 5
  • Report Guidance 6
  • Clinical Trials by Region 7
  • Clinical Trials and Average Enrollment by Country 8
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
  • Top Five Countries Contributing to Clinical Trials in Europe 11
  • Top Countries Contributing to Clinical Trials in North America 12
  • Top Countries Contributing to Clinical Trials in Middle East and Africa 13
  • Top Five Countries Contributing to Clinical Trials in Central and South America 14
  • Clinical Trials by G7 Countries: Proportion of Non-Alcoholic Steatohepatitis to Gastrointestinal Clinical Trials 15
  • Clinical Trials by Phase in G7 Countries 16
  • Clinical Trials in G7 Countries by Trial Status 17
  • Clinical Trials by E7 Countries: Proportion of Non-Alcoholic Steatohepatitis to Gastrointestinal Clinical Trials 18
  • Clinical Trials by Phase in E7 Countries 19
  • Clinical Trials in E7 Countries by Trial Status 20
  • Clinical Trials by Phase 21
  • In Progress Trials by Phase 22
  • Clinical Trials by Trial Status 23
  • Clinical Trials by End Point Status 24
  • Subjects Recruited Over a Period of Time 25
  • Clinical Trials by Sponsor Type 26
  • Prominent Sponsors 27
  • Top Companies Participating in Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials 28
  • Prominent Drugs 29
  • Latest Clinical Trials News on Non-Alcoholic Steatohepatitis 30
  • Nov 23, 2015: Can-Fite Announces Compelling Pre-Clinical Data on CF102 in the Treatment of Non-Alcoholic Steatohepatitis 30
  • Nov 19, 2015: MediciNova to Initiate Clinical Trial Evaluating MN-001 in NASH Patients With Hypertriglyceridemia 30
  • Nov 18, 2015: NASH Clinical Trail Surpasses 25% Patient Recruitment Milestone 31
  • Nov 16, 2015: GENFIT Announces Pivotal Phase 3 Clinical Trial of Elafibranor in NASH Following Regulatory Input 31
  • Nov 14, 2015: Intercept Presents New Data Analyses on Non-Invasive Liver Testing From FLINT Trial of Obeticholic Acid in Nonalcoholic Steatohepatitis at AASLD 2015 32
  • Nov 12, 2015: Albireo to Present A4250 Clinical Data at the 2015 AASLD Annual Meeting 33
  • Nov 11, 2015: DeuteRx Presents DRX-065 for the Treatment of NASH at the Annual Meeting of the American Association for the Study of Liver Diseases 34
  • Nov 09, 2015: NGM Bio to Present Data Highlighting the Therapeutic Potential of NGM282 in Cholestatic Liver Diseases at AASLD's The Liver Meeting 2015 34
  • Oct 05, 2015: Protalix BioTherapeutics to Explore Non Alcoholic Steato Hepatitis (NASH) as an Indication for Its PRX 106 Oral Anti TNF 35
  • Oct 01, 2015: Tobira Therapeutics Announces Presentations Related to Cenicriviroc's Development Program in NASH at the American Association for the Study of Liver Diseases Annual Meeting 35
  • Sep 21, 2015: Pharmaxis Releases Successful Results of Phase 1 Clinical Trial for Boehringer Ingelheim Partnered Drug PXS-4728A 36
  • Sep 16, 2015: Galectin Therapeutics Announces Start of Phase 2 Clinical Trial With GR-MD-02 in NASH With Advanced Fibrosis 36
  • Sep 14, 2015: Raptor Pharmaceutical Provides Topline Results From Phase 2b CyNCh Study Evaluating RP103 in Pediatric Nonalcoholic Steatohepatitis 37
  • Clinical Trial Profile Snapshots 38

Appendix 192

  • Abbreviations 192
  • Definitions 192
  • Research Methodology 193
  • Secondary Research 193
  • About GlobalData 194
  • Contact Us 194
  • Disclaimer 194
  • Source 195

List of Tables

List of Tables

  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials by Region, 2015* 7
  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8
  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2015* 10
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 11
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, North America, Top Countries, 2015* 12
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2015* 13
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2015* 14
  • Proportion of Non-Alcoholic Steatohepatitis to Gastrointestinal Clinical Trials, G7 Countries (%), 2015* 15
  • Non-Alcoholic Steatohepatitis Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 16
  • Non-Alcoholic Steatohepatitis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 17
  • Proportion of Non-Alcoholic Steatohepatitis to Gastrointestinal Clinical Trials, E7 Countries (%), 2015* 18
  • Non-Alcoholic Steatohepatitis Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 19
  • Non-Alcoholic Steatohepatitis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 20
  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials by Phase, 2015* 21
  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 22
  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials by Trial Status, 2015* 23
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, by End Point Status, 2015* 24
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 25
  • Non-Alcoholic Steatohepatitis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 26
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 27
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 28
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 29

List of Figures

List of Figures

  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials by Region (%), 2015* 7
  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8
  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2015* 10
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 11
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 12
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2015* 13
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2015* 14
  • Proportion of Non-Alcoholic Steatohepatitis to Gastrointestinal Clinical Trials, G7 Countries (%), 2015* 15
  • Non-Alcoholic Steatohepatitis Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 16
  • Non-Alcoholic Steatohepatitis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 17
  • Proportion of Non-Alcoholic Steatohepatitis to Gastrointestinal Clinical Trials, E7 Countries (%), 2015* 18
  • Non-Alcoholic Steatohepatitis Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 19
  • Non-Alcoholic Steatohepatitis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 20
  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials by Phase (%), 2015* 21
  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 22
  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials by Trial Status, 2015* 23
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, by End Point Status, 2015* 24
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 25
  • Non-Alcoholic Steatohepatitis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 26
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 27
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 28
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 29
  • GlobalData Methodology 193
Back to Top